Formulary Insights

Biopharma Must Transform its Payer Launch Playbook

US payers reject 69% of prescriptions during the first year of a new drug’s FDA approval, and these early rejection rates are only nominally improved in the ensuing years.1 Such a high payer rejection rate is stunning on its own, but this doesn’t even reflect the countless instances when healthcare providers, purely out of a learned […]